ISTALOL Drug Patent Profile

When do Istalol patents expire, and when can generic versions of Istalol launch?

Istalol is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in ISTALOL is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Istalol

A generic version of ISTALOL was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for ISTALOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	4,925
Drug Prices:	Drug price information for ISTALOL
What excipients (inactive ingredients) are in ISTALOL?	ISTALOL excipients list
DailyMed Link:	ISTALOL at DailyMed

See drug prices for ISTALOL

See drug sales revenues for ISTALOL

Recent Clinical Trials for ISTALOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bp Consulting, Inc	Phase 4

See all ISTALOL clinical trials

Pharmacology for ISTALOL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Paragraph IV (Patent) Challenges for ISTALOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ISTALOL	Ophthalmic Solution	timolol maleate	0.5%	021516	1	2012-10-19

US Patents and Regulatory Information for ISTALOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	ISTALOL	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021516-001	Jun 4, 2004	AT2	RX	Yes	Yes

Expired US Patents for ISTALOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb	ISTALOL	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021516-001	Jun 4, 2004
Bausch And Lomb	ISTALOL	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021516-001	Jun 4, 2004

International Patents for ISTALOL

See the table below for patents covering ISTALOL around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2307303	COLLYRES A LIBERATION PROLONGEE (PROLONGED-ACTION EYE DROP)
Spain	2297894
China	1278162
World Intellectual Property Organization (WIPO)	9922715
Germany	69839152
Japan	4377052
European Patent Office	1029537	COLLYRES A LIBERATION PROLONGEE (SUSTAINED RELEASE EYEDROPS)

Supplementary Protection Certificates for ISTALOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804

Market Dynamics and Financial Trajectory for ISTALOL

Last updated: March 23, 2026

What is ISTALOL and its current market status?

ISTALOL (timolol maleate) is a non-selective beta-adrenergic blocker approved primarily for the treatment of glaucoma and ocular hypertension. It is marketed globally by various ophthalmic drug companies. The drug has been on the market since the 1970s, with a well-established safety and efficacy profile.

What are the key factors influencing the ISTALOL market?

Market Size and Growth Potential

The global ophthalmic drugs market was valued at approximately USD 30 billion in 2022 and is projected to reach USD 42 billion by 2030, growing at a CAGR of around 4.2% (Fortune Business Insights, 2023). ISTALOL constitutes a significant portion of this segment, especially in glaucoma treatment.

Market Drivers

• Increase in glaucoma prevalence: An estimated 80 million people worldwide suffer from glaucoma, with projections reaching 110 million by 2040 (World Health Organization, 2022).
• Aging population: The rise in elderly demographics enlarges the patient base for intraocular pressure (IOP)-reducing drugs.
• Preservative-free formulations: Growing demand for preservative-free and fixed-dose combinations enhances ISTALOL's competitiveness.

Market Challenges

• Competition from generics: Since patent expiry, generic timolol maleate products dominate, leading to price erosion.
• New drug development: Longer-term developments include prostaglandin analogs and combination therapies that can replace or supplement ISTALOL.
• Side effects and patient adherence: Systemic absorption leading to cardiovascular side effects reduces patient compliance.

How does the financial trajectory look for ISTALOL?

Patent and Regulatory Status

ISTALOL has been off-patent in many jurisdictions since the late 1990s. Patent expirations have intensified generic competition. Regulatory approvals are widespread, with key markets including the U.S., EU, and Japan.

Revenue Trends

• Established markets: In the U.S., ISTALOL generates around USD 250 million annually, though this remains steady due to generic presence.
• Emerging markets: Rapid growth in countries such as India and China, where glaucoma diagnosis and treatment rates are increasing, may expand revenues by 5-7% annually over the next five years.
• Price erosion: A decline of 15-20% in unit pricing is typical post-patent expiry.

Investment and Development

Few companies invest heavily in reformulations or new indications for ISTALOL due to the high prevalence of generics and limited profit margins. Most revenue is derived from existing formulations; R&D expenditure is minimal.

Mergers, Acquisitions, and Market Entry

• Generic manufacturers dominate, with companies such as Sandoz, Teva, and Sun Pharma holding large market shares.
• Entry barriers are high for new competitors due to established distribution channels and product familiarity.

What are the future market trends?

Shift Toward Higher-value Therapies

Emerging therapies such as selective laser trabeculoplasty and novel pharmacologic agents could replace traditional beta-blockers like ISTALOL. The adoption rate of these therapies remains low but is increasing with technological advances.

Patent Landscape and Reformulation Strategies

Firms exploring fixed-dose combinations or preservative-free formulations aim to extend market share, but such innovations face limited commercialization due to high development costs and saturated markets.

Market Consolidation and Price Pressure

Industry consolidation exerts downward pressure on prices, favoring large-volume sales across generic portfolios.

What is the outlook for ISTALOL's financial trajectory over the next five years?

Year	Estimated Global Sales (USD millions)	Major Growth Drivers	Major Challenges
2023	300	Established use, aging populations	Generic price competition
2024-2026	280-310	Market saturation, price erosion	Competition from new therapies
2027-2028	250-280	Potential regulatory changes, slow uptake of alternatives	Market normalization

Supply chain disruptions or regulatory shifts could impact these projections.

Key Takeaways

1. ISTALOL remains a significant but declining contributor to the global glaucoma treatment market.
2. Patent expirations and generic competition impose significant price pressures.
3. Growth in emerging markets offers partial offset but is limited by market saturation.
4. R&D efforts focus on reformulations rather than new indications due to low profit margins.
5. The outlook suggests stabilized revenues with ongoing pressure from alternative therapies and generics.

FAQs

Q1. Is ISTALOL still under patent protection?
No. Patent expiration occurred in most markets during the late 1990s, leading to widespread generic availability.

Q2. What are the main competitors to ISTALOL?
Generic timolol formulations dominate; newer therapies include prostaglandin analogs like latanoprost and combination drugs such as brimonidine/timolol.

Q3. Can reformulations extend ISTALOL's market viability?
Yes. Fixed-dose combinations and preservative-free formulations could maintain some market share but face limited profitability margins.

Q4. Which regions present growth opportunities?
Emerging markets like India and China, driven by rising glaucoma prevalence and improving healthcare access, offer growth potential.

Q5. How does patient adherence impact ISTALOL sales?
Systemic absorption and side effects reduce adherence, influencing prescribing patterns and overall sales volumes.

---

References

[1] Fortune Business Insights. (2023). Ophthalmic drugs market size, share & industry analysis.

[2] World Health Organization. (2022). Glaucoma fact sheet.

[3] U.S. Food & Drug Administration. (2020). Drug Approvals and Patent Data.